Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA trimmed its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 6.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,133,931 shares of the company’s stock after selling 73,818 shares during the period. Pictet Asset Management Holding SA’s holdings in Kiniksa Pharmaceuticals were worth $22,429,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in KNSA. Wellington Management Group LLP acquired a new stake in shares of Kiniksa Pharmaceuticals in the third quarter valued at $1,192,000. JPMorgan Chase & Co. bought a new stake in Kiniksa Pharmaceuticals in the third quarter worth about $4,997,000. Parkman Healthcare Partners LLC lifted its holdings in Kiniksa Pharmaceuticals by 16.7% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company’s stock valued at $18,874,000 after acquiring an additional 108,102 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Kiniksa Pharmaceuticals during the 4th quarter valued at about $355,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Kiniksa Pharmaceuticals in the 3rd quarter worth approximately $1,105,000. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals Stock Performance

Kiniksa Pharmaceuticals stock opened at $22.21 on Tuesday. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of -158.63 and a beta of 0.48. The company has a 50 day moving average price of $20.84 and a 200 day moving average price of $21.95. Kiniksa Pharmaceuticals, Ltd. has a 52 week low of $16.56 and a 52 week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). The business had revenue of $122.50 million during the quarter, compared to analyst estimates of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals’s revenue for the quarter was up 46.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.35 EPS. Equities analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on KNSA shares. Wedbush reissued an “outperform” rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. Citigroup assumed coverage on Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a “buy” rating and a $40.00 price objective for the company. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals has a consensus rating of “Buy” and an average target price of $37.17.

Insider Activity at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 9,051 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $22.45, for a total value of $203,194.95. Following the completion of the sale, the chief accounting officer now directly owns 26,528 shares of the company’s stock, valued at $595,553.60. The trade was a 25.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Mark Ragosa sold 36,372 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $22.25, for a total transaction of $809,277.00. Following the transaction, the chief financial officer now owns 22,958 shares in the company, valued at approximately $510,815.50. This trade represents a 61.30 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 93,766 shares of company stock valued at $2,011,735. Insiders own 54.57% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.